Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout.

ABSTRACT:

Background

Patients with gout are at an increased risk of cardiovascular (CV) disease including myocardial infarction (MI), stroke, and heart failure (HF).

Objectives

The authors conducted a cohort study to examine comparative CV safety of the 2 gout treatments-probenecid and allopurinol-in patients with gout.

Methods

Among gout patients ≥65 years of age and enrolled in Medicare (2008 to 2013), those who initiated probenecid or allopurinol were identified. The primary outcome was a composite CV endpoint of hospitalization for MI or stroke. MI, stroke, coronary revascularization, HF, and mortality were assessed separately as secondary outcomes. The authors estimated the incidence rate and hazard ratio of the primary and secondary outcomes in the 1:3 propensity score-ma

SUBMITTER: Kim SC 

PROVIDER: S-EPMC5911395 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature